The European healthcare technology and medical technology landscape has entered a profound inflection point as it moves through 2025 and into 2026. This period is increasingly defined by a transition from the speculative fragmentation and "growth-at-all-costs" mindset of the early 2020s to a disciplined, professionalised era termed industrial maturity. For companies preparing to raise a Series C funding round in this environment, the requirements have shifted from simple user